Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review

Journal of Clinical Oncology

Volumn 28, Issue 17, 2010, Pages 2914-2924

  Lyman, Gary H ^a   Dale, David C ^a   Wolff, Debra A ^a   Culakova, Eva ^a   Poniewierski, Marek S ^a   Kuderer, Nicole M ^a   Crawford, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; DATA BASE; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; FOLLOW UP; GERM CELL TUMOR; HODGKIN DISEASE; HUMAN; LUNG SMALL CELL CANCER; LYMPHOMA; MANTEL HAENSZEL TEST; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; META-ANALYSIS AS TOPIC; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956400375     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.8723     Document Type: Review

References (58)

1. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
2. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993 (Pubitemid 23025731)
3. Clark OA, Lyman GH, Castro AA, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: A meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-4214, 2005 (Pubitemid 46211326)
4. Kuderer NM, Dale DC, Crawford J, et al: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 25:3158-3167, 2007 (Pubitemid 47218066)
5. Wittman B, Horan J, Lyman GH: Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: A meta-analysis of randomized controlled trials. Cancer Treat Rev 32: 289-303, 2006 (Pubitemid 44502006)
6. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453, 2006 (Pubitemid 44442936)
7. Crawford J, Armitage J, Balducci L, et al: Myeloid growth factors. J Natl Compr Canc Netw 7:64-83, 2009
8. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
9. Castro GA, Church A, Pechet L, et al: Leukemia after chemotherapy of Hodgkin's disease. N Engl J Med 289:103-104, 1973
10. Preisler HD, Lyman GH: Acute myelogenous leukemia subsequent to therapy for a different neoplasm: Clinical features and response to therapy. Am J Hematol 3:209-218, 1977 (Pubitemid 8261721)
11. Leone G, Pagano L, Ben-Yehuda D, et al: Therapy-related leukemia and myelodysplasia: Susceptibility and incidence. Haematologica 92:1389-1398, 2007 (Pubitemid 350144157)
12. Le Deley MC, Suzan F, Cutuli B, et al: Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: Risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25:292-300, 2007 (Pubitemid 350003017)
13. Praga C, Bergh J, Bliss J, et al: Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23:4179-4191, 2005 (Pubitemid 46211324)
14. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 21:1195-1204, 2003 (Pubitemid 46894010)
15. Crump M, Tu D, Shepherd L, et al: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3066-3071, 2003 (Pubitemid 46606286)
16. Kalaycio M, Rybicki L, Pohlman B, et al: Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. J Clin Oncol 24:3604-3610, 2006 (Pubitemid 46630533)
17. Patt DA, Duan Z, Fang S, et al: Acute myeloid leukemia after adjuvant breast cancer therapy in older women: Understanding risk. J Clin Oncol 25: 3871-3876, 2007 (Pubitemid 47477263)
18. Hershman D, Neugut AI, Jacobson JS, et al: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196-205, 2007
19. Relling MV, Boyett JM, Blanco JG, et al: Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101:3862-3867, 2003 (Pubitemid 36857858)
20. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
21. Sterne JA, Egger M: Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol 54:1046-1055, 2001 (Pubitemid 32888370)
22. Sterne JA, Egger M, Smith GD: Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323:101-105, 2001 (Pubitemid 32681979)
23. Thornton A, Lee P: Publication bias in metaanalysis: Its causes and consequences. J Clin Epidemiol 53:207-216, 2000 (Pubitemid 30151226)
24. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
25. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997 (Pubitemid 27387172)
26. Patil KD: Cochran's Q test: Exact distribution. J Am Stat Assoc 70:186-189, 1975
27. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003 (Pubitemid 37088507)
28. Cochran WG: The combination of estimates from different experiments. Biometrics 10:101-129, 1954
29. Burnell MJI, Levine MN, Chapman JA, et al: A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA. 21). J Clin Oncol 25:15s, 2007 (suppl; abstr 550)
30. Burton C, Linch D, Hoskin P, et al: A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer 94:806-813, 2006
31. Chevallier B, Chollet P, Merrouche Y, et al: Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564-1571, 1995
32. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
33. Clamp AR, Ryder WD, Bhattacharya S, et al: Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. Br J Cancer 99:253-258, 2008
34. Diehl V, Franklin J, Pfistner B, et al: Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9). J Clin Oncol 25:444s, 2007 (suppl; abstr LBA8015)
35. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
36. Doorduijn JK, van der Holt B, van Imhoff GW, et al: CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 21:3041-3050, 2003 (Pubitemid 46606283)
37. Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 22:2159-2166, 2004 (Pubitemid 41095150)
38. Fleming GF, Filiaci VL, Bentley RC, et al: Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol 15:1173-1178, 2004 (Pubitemid 39199303)
39. Fossa SD, Kaye SB, Mead GM, et al: Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy: European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716-724, 1998
40. Fukuoka M, Masuda N, Negoro S, et al: CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75:306-309, 1997 (Pubitemid 27019579)
41. Fumoleau P, Chauvin F, Namer M, et al: Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol 19:612-620, 2001 (Pubitemid 32119075)
42. Gatzemeier U, Kleisbauer JP, Drings P, et al: Lenograstim as support for ACE chemotherapy of small-cell lung cancer: A phase III, multicenter, randomized study. Am J Clin Oncol 23:393-400, 2000 (Pubitemid 32429154)
43. Gisselbrecht C, Haioun C, Lepage E, et al: Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: Factors influencing chemotherapy administration-Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 25:289-300, 1997 (Pubitemid 27248180)
44. Pan D, Qin J, Farber C, et al: CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas. Leuk Lymphoma 44: 967-971, 2003 (Pubitemid 36416993)
45. Papaldo P, Lopez M, Cortesi E, et al: Addition of either lonidamine or granulocyte colonystimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21:3462-3468, 2003 (Pubitemid 46603516)
46. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
47. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004 (Pubitemid 38970554)
48. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004 (Pubitemid 38970553)
49. Pfreundschuh M, Zwick C, Zeynalova S, et al: Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 19:545-552, 2008
50. Sternberg CN, de Mulder P, Schornagel JH, et al: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and GCSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42:50-54, 2006 (Pubitemid 41814532)
51. Sternberg CN, de Mulder PH, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638-2646, 2001 (Pubitemid 32441368)
52. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCICSAKK multicenter study. J Clin Oncol 21:843-850, 2003 (Pubitemid 46606444)
53. Venturini M, Del Mastro L, Aitini E, et al: Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 97:1724-1733, 2005 (Pubitemid 41782282)
54. Verdonck LF, Notenboom A, de Jong DD, et al: Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: A phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 109:2759-2766, 2007
55. Veyret C, Levy C, Chollet P, et al: Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: Tenyear results from the French Adjuvant Study Group GETIS 02 Trial. Cancer 107:2535-2544, 2006 (Pubitemid 44845605)
56. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 13:652-659, 1995
57. Zinzani PL, Pavone E, Storti S, et al: Randomized trial with or without granulocyte colonystimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 89:3974-3979, 1997 (Pubitemid 27220941)
58. Josting A, Wiedenmann S, Franklin J, et al: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3440-3446, 2003 (Pubitemid 46594076)